MELD Na as a prognostic score for cirrhotic patients
Main Article Content
Abstract
Background-The high mortality of cirrhosis is a global public health problem. For predicting the outcome of patients with cirrhosis, many prognostic models were proposed.The new Model for End-Stage Liver Disease including serum sodium
(MELD-Na) has been proposed as an alternative to the original MELD, to increase the accuracy of the score in predicting short-term mortality. The purpose of this study was to assess the ability of MELD-Na scoring system to predict three-month mortality among cirrhotic patients, and comparing it to the MELD score.
Methods-An observational study was carried out, at the Hepato-Gastro-Enterology Department of the University Hospital Center of Oran. A retrospective review of the medical records of all patients with cirrhosis, between 1st January 2019 and 31st December 2021, was performed. Among 103 patients, 47 were selected after excluding the patients who were lost to follow-up after three months or with missing data. The information collected included demographic data, clinical characteristics and laboratory values of: bilirubin, creatinine, international normalized ratio (INR) of prothrombin and sodium. The MELDNa and MELD scores were calculated using online calculators, then the ability of the models to predict the risk of mortality at three months was assessed, using the area under the receiver operating characteristic curve (AUC).
Results - : Eight (17%) patients died at three months. The MELD-Na and MELD both had significantly high area under the curve (AUC): MELD-Na: 0.952, 95% confidence interval [CI]: 0.885–1.00, MELD: 0.931, 95% confidence interval [CI]: 0.834–1.000. The MELD-Na score was slightly better than the MELD, with a sensitivity and a specificity of 87.5% and
87.2%, respectively, for a cut-off value = 21.
Conclusion -The MELD-Na score seems to be a good predictor of mortality at three months among patients with cirrhosis.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
A- Open Access statement and license:
1-Open Access statement:
JFMO provides immediate open access to published content in support of the idea that free access to research helps support the dissemination of knowledge and ideas in the field of medical science. All articles will be published under Creative Commons licenses.
All published data is immediate free access to the work and permits any user to read, download, copy, distribute print, search, or link to the full texts of articles.
The users of any published material in the JFMO must act in accordance with the Creative Commons Licenses CC BY-NC-ND 4.0.
2-License:
All published data is distributed following the Creative Commons Licenses CC BY-NC-ND 4.0. This license is allowing others to download the works and share them with others as long as they correctly cite the manuscript, No changes are allowed to the original manuscript and the manuscript must be used only for non for profit or non-commercial purposes.
This work is licensed under a Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International License.
3-Self Archiving:
Authors are permitted and encouraged to share online their articles published in JFMO (e.g., in institutional repositories or on their website), as it can lead to productive exchanges, as well as earlier and greater citation of published work.